Systemic sclerosis (SSc) is a multisystem autoimmune disease characterised by microvascular damage and excessive fibrosis of the skin and various internal organs. Limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) subsets are also associated with the presence of a number of autoantibodies, the expression of which can be useful in the diagnosis, prognosis and SSc disease management.[@R1]

The European Medicines Agency (EMA) requested the establishment of a prospective registry of patients with ongoing digital ulcers associated with SSc as a licensing requirement for bosentan in this indication. The Digital Ulcers Outcome (DUO) Registry enrols patients with digital ulcer disease regardless of their treatment status; however, a large proportion are receiving bosentan. This study provides valuable insights into this patient group and here we describe the clinical and autoantibody characteristics of these patients at enrolment.

Methods {#s1}
=======

The DUO Registry was initiated in April 2008 as an EMA postapproval commitment (after approval of a new indication for bosentan 'to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease').[@R2] Participating centres received approval from relevant national and local ethics committees, data protection and health authorities. In line with an observational study design, physicians were asked to enter all consenting consecutive patients with ongoing digital ulcers associated with SSc, irrespective of treatment regimen. Patients received standard medical care and follow-up as determined by their physician. Data definitions were informed by literature[@R3] and scientific committee consensus. Data collection included demographics, SSc disease duration, underlying disease classification (lcSSc, dcSSc, overlap SSc/mixed connective tissue disease and other), internal organ manifestations, autoantibodies, history of interventions/complications related to digital ulcers, ongoing complications related to digital ulcers, and ongoing medications and functional assessment based on a disease-specific questionnaire. The presence of antinuclear antibodies, anti-scleroderma-70 antibodies, anticentromere antibodies (ACA), anti-RNA polymerase 3, anti-U1 ribonucleoprotein and anti-U3 ribonucleoprotein were recorded. All serology tests and other data collection parameters were collected if performed. Quality assurance comprised automatic online quality checks and annual source data verification on 10% of the patients.

Data analysis {#s2}
-------------

Enrolment data for the antibody subsets were analysed cross-sectionally for differences by group. SAS statistical software was used for analysing the data. Descriptive statistics (mean, median, SD, 95% CI, minimum, maximum) are provided for numerical variables. Categorical variables are summarised by counts and percentages and 95% CI.

Results {#s3}
=======

As of 19 November 2010, a total of 2439 patients had been enrolled into the DUO Registry from 271 participating centres in 18 European countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland and UK).

Study cohort characteristics {#s4}
----------------------------

The mean age of the patients enrolled was 54.6 years (SD 14.1) and the majority were women. Age at first Raynaud\'s phenomenon was on average 39.8 years and age at first digital ulcer was 46.7 years. At the time of enrolment, 60.0% (1426/2377) had at least one digital ulcer (data were missing for 62 patients). All patients who had no current digital ulcers at enrolment had a history of digital ulcer disease. Overall, 52.2% of the patients were classified as lcSSc, 36.9% as dcSSc, 6.8% as overlap SSc/mixed connective tissue disease, and 4.1% had other diseases (eg, systemic lupus erythematosus, dermatomyositis, vasculitis or SSc not further specified) (data were missing for 44 patients).

At enrolment, gastrointestinal tract manifestations had occurred in more than half of the patients (55.7%). Also common were lung fibrosis (41.3%), pulmonary arterial hypertension (PAH) (15.0%) and heart manifestations (10.7%). Almost half of all patients (47.4%) were receiving treatment with bosentan or another ERA (endothelin receptor antagonist), with a similar proportion receiving calcium antagonists and approximately one third receiving prostanoids (see supplementary table S1, available online only).

Antibody distribution {#s5}
---------------------

Almost all, 95.7%, (2085/2179) of patients tested were positive for antinuclear antibodies, 45.2% (854/1888) for anti-scleroderma-70 antibodies, 43.6% (775/1778) for ACA, 9.9% (86/867) for anti-RNA polymerase 3, 9.7% (120/1243) for anti-U1 ribonucleoprotein and 4.9% (39/799) for anti-U3 ribonucleoprotein. Few patients had a combination of antibodies. The combination with the highest occurrence was anti-scleroderma-70 plus ACA, 2.3% (56/2439), followed by anti-scleroderma-70 plus anti-U1 ribonucleoprotein, 1.8% (43/2439), anti-scleroderma-70 plus anti-RNA polymerase 3, 1.5% (36/2439), ACA plus anti-U1 ribonucleoprotein, 1.4% (34/2439), ACA plus anti-RNA polymerase 3, 1.4% (34/2439) and anti-U1 ribonucleoprotein plus anti-U3 ribonucleoprotein, 1.3% (31/2439).

SSc disease characteristics by antibody status {#s6}
----------------------------------------------

Patients positive for ACA were predominantly classified as lcSSc (82.9%; [table 1](#T1){ref-type="table"}). From the patients positive for anti-scleroderma-70 antibodies, a high proportion were classified as dcSSc (66.6%) and a lower proportion were classified as lcSSc (29.4%). Lung fibrosis was most frequent in the anti-scleroderma-70 subset (62.2%) compared with other antibody subsets (22.3--41.9%). Gastrointestinal manifestations showed a similar high proportion in all antibody subgroups, except for patients who were anti-U3 ribonucleoprotein positive. The frequencies of PAH and kidney manifestations were generally similar across the antibody subsets, although the proportion among patients with anti-U3 ribonucleoprotein was slightly higher; heart manifestations were highest in patients with anti-scleroderma-70 and anti-U1 ribonucleoprotein and lowest in patients with ACA ([table 2](#T2){ref-type="table"}). The proportion of patients with previous digital ulcer complications and interventions was broadly similar in the anti-scleroderma-70 subgroup and the ACA subgroup; the most marked exception was for surgical amputation, which occurred almost twice as frequently in patients with ACA (14.6%) compared with anti-scleroderma-70-positive patients (7.9%) ([table 3](#T3){ref-type="table"}).

###### 

Demographics and clinical features by antibody status

                                                                                      ANA[\*](#T1FN1){ref-type="table-fn"} (N=2085)   Anti-Scl-70 (N=854)             Anti-RNA Pol 3 (N=86)         ACA (N=775)                     Anti-U1 RNP (N=120)            Anti-U3 RNP (N=39)
  ----------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------- ------------------------------- ------------------------------ -----------------------------
  Tested positive/tests performed (%)                                                 2085/2179 (95.7)                                854/1888 (45.2)                 86/867 (9.9)                  775/1778 (43.6)                 120/1243 (9.7)                 39/799 (4.9)
  Female, n/N (%)                                                                     1719/2085 (82.4)                                676/854 (79.2)                  70/86 (81.4)                  677/775 (87.4)                  91/120 (75.8)                  31/39 (29.5)
  dcSSc, n/N (%) (95% CI)                                                             776/2070 (37.5) (35.4 to 39.6)                  557/848 (65.7) (62.4 to 68.9)   37/85 (43.5) (32.8 to 54.7)   91/770 (11.8) (9.6 to 14.3)     34/119 (28.6) (20.7 to 37.6)   10/38 (26.3) (13.4 to 43.1)
  lcSSc, n/N (%) (95% CI)                                                             1071/2070 (51.7) (49.6 to 53.9)                 249/848 (29.4) (26.3 to 32.6)   28/85 (32.9) (23.1 to 44.0)   638/770 (82.9) (80.0 to 85.5)   38/119 (31.9) (23.7 to 41.1)   15/38 (39.5) (24.0 to 56.6)
  Overlap SSc/mCTD, n/N (%) (95% CI)                                                  149/2070 (7.2) (6.1 to 8.6)                     17/848 (2.0) (1.2 to 3.2)       14/85 (16.5) (9.3 to 26.1)    23/770 (3.0) (1.9 to 4.5)       40/119 (33.6) (25.2 to 42.8)   12/38 (31.6) (17.5 to 48.7)
  Age at enrolment, years, mean (95% CI)                                              54.4 (53.8 to 55.0)                             52.4 (51.4 to 53.3)             51.3 (48.4 to 54.2)           58.1 (57.2 to 59.1)             49.9 (47.4 to 52.5)            48.5 (44.0 to 53.0)
  Age at RP onset, years, mean (95% CI)                                               39.7 (39.0 to 40.5)                             38.5 (37.5 to 39.6)             37.6 (34.7 to 40.6)           41.1 (39.9 to 42.3)             35.7 (32.9 to 38.6)            33.7 (28.5 to 38.9)
  Age at first digital ulcer, years, mean (95% CI)                                    46.6 (45.9 to 47.4)                             44.7 (43.6 to 45.7)             44.1 (41.1 to 47.2)           50.1 (48.9 to 51.3)             42.6 (39.6 to 45.5)            38.8 (33.6 to 44.0)
  Time from onset of RP to first digital ulcer, years, mean (95% CI)                  6.6 (6.2 to 7.0)                                6.0 (5.4 to 6.6)                6.1 (4.4 to 7.8)              8.1 (7.3 to 9.0)                6.5 (4.9 to 8.0)               6.9 (3.5 to 10.4)
  Time from first non-RP to first digital ulcer manifestation, years, mean (95% CI)   3.6 (3.3 to 3.9)                                3.2 (2.9 to 3.6)                3.6 (2.5 to 4.8)              3.9 (3.4 to 4.5)                3.8 (2.7 to 4.9)               4.6 (1.9 to 7.4)

The denominator N varies according to the number of available observations.

Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups.

ACA, anticentromere antibodies; ANA, antinuclear antibodies; anti-Scl-70, anti-scleroderma-70 antibodies; anti-RNA Pol 3, anti-RNA polymerase 3; anti-U1 RNP, anti-U1 ribonucleoprotein; anti-U3 RNP, anti-U3 ribonucleoprotein; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; mCTD, mixed connective tissue disease; RP, Raynaud\'s phenomenon; SSc, systemic sclerosis.

###### 

Disease manifestations by antibody status

                                                      ANA (N=2085)                      Anti-Scl-70 (N=854)             Anti-RNA Pol 3 (N=86)         ACA (N=775)                     Anti-U1 RNP (N=120)            Anti-U3 RNP (N=39)
  --------------------------------------------------- --------------------------------- ------------------------------- ----------------------------- ------------------------------- ------------------------------ -----------------------------
  Lung fibrosis, n/N (%) (95% CI)                     873/2085 (41.9) (39.7 to 44.0)    531/854 (62.2) (58.8 to 65.4)   36/86 (41.9) (31.3 to 53.0)   173/775 (22.3) (19.4 to 25.4)   50/120 (41.7) (32.7 to 51.0)   16/39 (41.0) (25.6 to 57.9)
  PAH, n/N (%) (95% CI)                               307/2085 (14.7) (13.2 to 16.3)    133/854 (15.6) (13.2 to 18.2)   12/86 (14.0) (7.4 to 23.1)    120/775 (15.5) (13.0 to 18.2)   19/120 (15.8) (9.8 to 23.6)    9/39 (23.1) (11.1 to 39.3)
  Kidney manifestations, n/N (%) (95% CI)             105/2085 (5.0) (4.1 to 6.1)       43/854 (5.0) (3.7 to 6.7)       7/86 (8.1) (3.3 to 16.1)      26/775 (3.4) (2.2 to 4.9)       10/120 (8.3) (4.1 to 14.8)     5/39 (12.8) (4.3 to 27.4)
  Gastrointestinal manifestations, n/N (%) (95% CI)   1192/2085 (57.2) (55.0 to 59.3)   498/854 (58.3) (56.4 to 63.9)   51/86 (59.3) (47.9 to 70.8)   440/775 (56.8) (53.2 to 60.3)   63/120 (52.5) (43.2 to 61.7)   15/39 (38.5) (23.4 to 55.4)
  Heart manifestations, n/N (%) (95% CI)              220/2085 (10.6) (9.3 to 12.0)     105/854 (12.3) (10.2 to 14.7)   6/86 (7.0) (2.6 to 14.6)      47/775 (6.1) (4.5 to 8.0)       16/120 (13.3) (7.8 to 20.7)    3/39 (7.7) (1.6 to 20.9)

The denominator N varies according to the number of available observations.

Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups.

ACA, anticentromere antibodies; ANA, antinuclear antibodies; anti-Scl-70, anti-scleroderma-70 antibodies; anti-RNA Pol 3, anti-RNA polymerase 3; anti-U1 RNP, anti-U1 ribonucleoprotein; anti-U3 RNP, anti-U3 ribonucleoprotein; PAH, pulmonary arterial hypertension.

###### 

Previous digital ulcer complications and interventions by antibody status

                                                                                                                   ANA[\*](#T3FN1){ref-type="table-fn"} (N=2085)   Anti-Scl-70 (N=854)             Anti-RNA Pol 3 N=86           ACA (N=775)                     Anti-U1 RNP (N=120)            Anti-U3 RNP (N=39)
  ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------- ------------------------------- ------------------------------ -----------------------------
  Previous digital ulcer complications                                                                                                                                                                                                                                                          
  Previous critical digital ischaemia, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                           459/867 (52.9) (49.6 to 56.3)                   174/340 (51.2) (45.7 to 56.6)   13/19 (68.4) (43.4 to 87.4)   178/321 (55.5) (49.8 to 61.0)   25/47 (53.2) (38.1 to 67.9)    12/17 (70.6) (44.0 to 89.7)
  Previous gangrene, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                             442/1960 (22.6) (20.7 to 24.5)                  171/792 (21.6) (18.8 to 24.6)   14/83 (16.9) (9.5 to 26.7)    181/739 (24.5) (21.4 to 27.8)   28/114 (24.6) (17.0 to 33.5)   11/38 (28.9) (15.4 to 45.9)
  Previous autoamputation, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                       169/1965 (8.6) (7.4 to 9.9)                     86/796 (10.8) (8.7 to 13.2)     4/82 (4.9) (1.3 to 12.0)      51/740 (6.9) (5.2 to 9.0)       9/115 (7.8) (3.6 to 14.3)      4/38 (10.5) (2.9 to 24.8)
  Previous soft tissue infection requiring systemic antibiotics, total, n/N[\*](#T3FN1){ref-type="table-fn"} (%)   601/1876 (32.0) (29.9 to 34.2)                  243/768 (31.6) (28.4 to 35.1)   18/78 (23.1) (14.3 to 34.0)   257/712 (36.1) (32.6 to 39.7)   30/109 (27.5) (19.4 to 36.9)   14/35 (40.0) (23.9 to 57.9)
  Previous osteomyelitis, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                        69/1952 (3.5) (2.8 to 4.5)                      31/793 (3.9) (2.7 to 5.5)       1/82 (1.2) (0.03 to 6.6)      33/735 (4.5) (3.1 to 6.3)       6/114 (5.3) (2.0 to 11.1)      5/37 (13.5) (4.5 to 28.8)
  Previous digital ulcer interventions                                                                                                                                                                                                                                                          
  Previous hospitalisation for digital ulcer, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                    870/1974 (44.1) (41.9 to 46.3)                  340/805 (42.2) (38.8 to 45.7)   30/80 (37.5) (26.9 to 49.0)   356/743 (47.9) (44.3 to 51.6)   53/111(47.7) (38.2 to 57.4)    16/35 (45.7) (28.8 to 63.4)
  Previous upper limb sympathectomy, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                             74/1922 (3.9) (3.0 to 4.8)                      21/768 (2.7) (1.7 to 4.2)       3/82 (3.7) (0.8 to 10.3)      43/720 (6.0) (4.4 to 8.0)       4/113 (3.5) (1.0 to 8.8)       1/36 (2.8) (0.1 to 14.5)
  Previous digital sympathectomy, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                40/1921 (2.1) (1.5 to 2.8)                      15/767 (2.0) (1.1 to 3.2)       3/82 (3.7) (0.8 to 10.3)      22/721 (3.1) (1.9 to 4.6)       2/113 (1.8) (0.2 to 6.3)       1/36 (2.8) (0.1 to 14.5)
  Previous arterial reconstruction, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                              20/1918 (1.0) (0.6 to 1.6)                      6/767 (0.8) (0.3 to 1.7)        2/82 (2.4) (0.3 to 8.5)       12/716 (1.7) (0.9 to 2.9)       2/113 (1.8) (0.2 to 6.3)       1/36 (3.0) (0.1 to 15.8)
  Previous arthrodesis, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                          31/1642 (1.9) (1.3 to 2.7)                      12/638 (1.9) (1.0 to 3.3)       1/70 (1.4) (0.04 to 7.7)      10/607 (1.6) (0.8 to 3.0)       2/99 (2.0) (0.3 to 7.1)        1/33 (3.0) (0.1 to 15.8)
  Previous debridement, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                          189/1644 (11.5) (10.0 to 13.1)                  49/491 (10.0) (8.2 to 13.1)     8/71 (11.3) (5.0 to 21.0)     90/608 (14.8) (12.1 to 17.9)    10/97 (10.3) (5.1 to 18.1)     3/33 (9.1) (1.9 to 24.3)
  Previous surgical amputation, n/N[\*](#T3FN1){ref-type="table-fn"} (%) (95% CI)                                  158/1661 (9.5) (8.1 to 11.0)                    51/642 (7.9) (6.0 to 10.3)      6/72 (8.3) (3.1 to 17.3)      90/618 (14.6) (11.9 to 17.6)    10/103 (9.7) (4.8 to 17.1)     4/34 (11.8) (3.3 to 27.5)
  Previous use of parenteral prostanoids, n/N[\*](#T3FN1){ref-type="table-fn"} (%) 95% CI)                         1112/1907 (58.3) (56.1 to 60.5)                 462/775 (59.6) (56.1 to 63.1)   37/81 (45.7) (34.6 to 57.1)   411/707 (58.1) (54.4 to 61.8)   62/113 (54.9) (45.2 to 64.2)   15/36 (41.7) (25.5 to 59.2)

The denominator N varies according to the number of available observations.

Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups.

ACA, anticentromere antibodies; ANA, antinuclear antibodies; anti-Scl-70, anti-scleroderma-70 antibodies; anti-RNA Pol 3, anti-RNA polymerase 3; anti-U1 RNP, anti-U1 ribonucleoprotein; anti-U3 RNP, anti-U3 ribonucleoprotein.

Onset of disease manifestations by antibody status {#s7}
--------------------------------------------------

In anti-scleroderma-70-positive patients, the first digital ulcer occurred at a mean age of 44.7 years (95% CI 43.6 to 45.7), whereas in ACA-positive patients, the first digital ulcer occurred approximately 6 years later, at 50.1 years (95% CI 48.9 to 52.3).

Compared with ACA-positive patients, anti-scleroderma-70-positive patients were younger at the onset of first Raynaud\'s phenomenon symptoms (anti-scleroderma-70: 38.5 years (95% CI 37.5 to 39.6); ACA: 41.1 years (95% CI 39.9 to 42.3)) and had shorter time periods from the onset of Raynaud\'s phenomenon to the first digital ulcer (anti-scleroderma-70: 6.0 years (95% CI 5.4 to 6.6); ACA: 8.1 years (95% CI 7.3 to 9.0)) ([table 1](#T1){ref-type="table"}).

Discussion {#s8}
==========

The findings of the DUO Registry regarding the burden of disease in SSc patients with digital ulcers confirm the findings of other large cohort studies.[@R4] [@R5] Organ manifestations are common, with gastrointestinal manifestations being the most frequently reported, followed by lung fibrosis, PAH and heart manifestations.

Complications associated with digital ulcers, such as infection requiring systemic antibiotics, gangrene and amputation occurred frequently in all major SSc subsets. Anti-scleroderma-70-positive patients were younger at the onset of the first digital ulcer and had approximately double the rate of lung fibrosis compared with ACA-positive patients, these data are in line with findings from the European League Against Rheumatism Scleroderma Trials and Research.[@R4] Furthermore, heart manifestations were also more common in the anti-scleroderma-70-positive group. Taken together, these findings confirm the association between anti-scleroderma-70 and more severe disease seen in other studies.[@R1]

The data show that anti-scleroderma-70-positive patients have fewer surgical amputations than ACA-positive patients but more autoamputation. As patients with this antibody have more SSc disease manifestations, the physician may be more reluctant to perform surgical interventions with the patient being more likely to be left to autoamputation; whereas ACA-positive patients may have a phenotype that leads to a decision to amputate surgically.

The proportion of anti-U1 ribonucleoprotein in patients with SSc, at approximately 30% in both lcSSc and dcSSc, was much higher than the previously reported figures.[@R1] In contrast to other studies, the presence of anti-U1 ribonucleoprotein did not appear to have a greater association with PAH or with gastrointestinal manifestations than other autoantibodies.[@R1]

The proportion of patients reported here as anti-U3 ribonucleoprotein positive was low (4.9%), a finding similar to that reported in other studies.[@R1] In addition, the complications associated with anti-U3 ribonucleoprotein positivity were similar as in previous studies.[@R6]--[@R10]

There are a number of limitations in this study. The DUO Registry is an observational study and not all data fields were completed for every patient; for example, the number of digital ulcers at enrolment was missing for 62 patients and few patients were tested for anti-RNA polymerase 3 or for anti-U3 ribonucleoprotein antibodies. Central testing was not performed and therefore potential variations between different analysis methods should be considered when interpreting the data.

In addition, at enrolment, differential recall bias for data recorded in the past may confound interpretation.

Almost half of all patients were being treated with bosentan. This is likely to be a reflection of the fact that the DUO Registry was initiated following EMA approval of bosentan,[@R2] and it is possible that patient entry into the registry was biased towards patients receiving bosentan. Therefore, there are limitations in the application of these data to the wider SSc population. Nevertheless, this study provides, and will continue to provide, valuable prospectively collected data from a large cohort of over 2000 SSc patients. The strengths include the prospective nature of data collection and the strong framework of research governance compared with that of previous studies. The multinational and multicentre nature of this registry offers the potential for comparison of different patient populations and healthcare systems.

Conclusion {#s9}
==========

This report provides the first analysis of data from the large, multinational DUO Registry confirming the high clinical burden of digital ulcers in patients with SSc across antibody subsets, with early occurrence and high frequency in patients with dcSSc. The feasibility and utility of the DUO Registry is confirmed by the findings of this study.
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